193.33

0.54% -1.05

After Hours: 193.00 -0.33 -0.17%

Madrigal Pharmaceuticals Inc (MDGL)

Overview News Price History Option Chain Why MDGL Down? Discussions Forecast Stock Split

Madrigal Pharmaceuticals Inc stock is currently priced at $193.33, with a 24-hour trading volume of 452.88K. It has seen a -0.54% decreased in the last 24 hours and a -21.92% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $195.2 pivot point. If it approaches the $189.4 support level, significant changes may occur.

Previous Close:

$194.38

Open:

$192.49

24h Volume:

452.88K

Market Cap:

$4.05B

Revenue:

Net Income/Loss:

$-373.63M

P/E Ratio:

-10.05

EPS:

-19.24

Net Cash Flow:

$-325.71M

1W Performance:

-8.82%

1M Performance:

-21.92%

6M Performance:

+54.78%

1Y Performance:

-37.08%

1D Range:

$189.00

$195.58

52W Range:

$119.76

$322.67

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Name

Madrigal Pharmaceuticals Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

484-380-9263

Address

Four Tower Bridge, Suite 400 200 Barr Harbor Drive, West Conshohocken, PA

Employee

Twitter

@MadrigalPharma

Next Earnings Date

2024-05-07

Latest SEC Filings

MDGL's Discussions on Twitter

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-22	Reiterated	Oppenheimer	Outperform
Dec-19-22	Reiterated	H.C. Wainwright	Buy
Dec-19-22	Reiterated	Piper Sandler	Overweight
Dec-19-22	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-08-22	Downgrade	B. Riley Securities	Buy → Neutral
Oct-07-21	Initiated	Jefferies	Buy
Aug-06-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
May-20-21	Resumed	Goldman	Buy
Nov-24-20	Resumed	Evercore ISI	Outperform
Nov-06-20	Reiterated	H.C. Wainwright	Buy
Jul-31-20	Initiated	Piper Sandler	Overweight
Jun-05-20	Initiated	BMO Capital Markets	Market Perform
May-05-20	Initiated	Chardan Capital Markets	Buy
Jan-30-20	Initiated	Canaccord Genuity	Buy
Jan-09-20	Upgrade	UBS	Neutral → Buy
Nov-07-19	Reiterated	H.C. Wainwright	Buy
Jun-25-19	Initiated	Stifel	Hold
Jun-10-19	Upgrade	B. Riley FBR	Neutral → Buy
Feb-28-19	Reiterated	H.C. Wainwright	Buy
Feb-22-19	Initiated	SVB Leerink	Outperform
Jan-23-19	Initiated	UBS	Neutral
Dec-14-18	Initiated	Wolfe Research	Outperform
Dec-12-18	Initiated	B. Riley FBR	Neutral
Nov-19-18	Downgrade	Raymond James	Mkt Perform → Underperform
Nov-16-18	Upgrade	Evercore ISI	In-line → Outperform
Sep-04-18	Initiated	Citigroup	Buy
Aug-06-18	Downgrade	Goldman	Buy → Neutral
Jun-28-18	Initiated	Raymond James	Mkt Perform

View All

Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News

Madrigal Statement on the Passing of Dr. Stephen Harrison

GlobeNewswire Inc.

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

2 Under-the-Radar Growth Stocks to Consider

The Motley Fool

Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics

The Motley Fool

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

1 No-Brainer Growth Stock to Buy Now

The Motley Fool

Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data

Madrigal Pharmaceuticals Inc (MDGL) Net Income 2024

MDGL net income (TTM) was -$373.63 million for the quarter ending December 31, 2023, a -26.50% decrease year-over-year.

Madrigal Pharmaceuticals Inc (MDGL) Cash Flow 2024

MDGL recorded a free cash flow (TTM) of -$325.71 million for the quarter ending December 31, 2023, a -44.71% decrease year-over-year.

Madrigal Pharmaceuticals Inc (MDGL) Earnings per Share 2024

MDGL earnings per share (TTM) was -$19.98 for the quarter ending December 31, 2023, a -15.96% decline year-over-year.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.